Form 8-K

8-K — CorMedix Inc.

Accession: 0001213900-26-047748

Filed: 2026-04-27

Period: 2026-04-27

CIK: 0001410098

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0287640-8k_cormedix.htm (Primary)

EX-99.1 — PRESS RELEASE DATED APRIL 27, 2026 (ea028764001ex99-1.htm)

GRAPHIC (ea0287640_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0287640-8k_cormedix.htm · Sequence: 1

false

0001410098

2026-04-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 27, 2026

CORMEDIX INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-34673

20-5894890

(State

or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

389 Interpace Parkway, Suite 450

Parsippany, NJ

07054

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (908) 517-9500

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see

General Instruction A.2, below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.001 par value

CRMD

Nasdaq Global Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On April 27, 2026, CorMedix, Inc. (the “Company”

or “CorMedix”) issued a press release announcing an update related to the initial readout of topline data for the Phase III

study (ReSPECT) assessing REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal infections. A copy of the press release

is furnished as Exhibit 99.1, attached hereto.

The information in this Item 7.01 (including Exhibit

99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under

the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific

reference in such a filing.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking

statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section

21E of the Exchange Act, that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words

such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,”

“estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,”

“should,” “target,” “will,” “would,” and similar expressions or variations intended to

identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations,

beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements including, but not limited to statements

regarding the risk that topline data from CorMedix’s and its partners’ clinical trials, including the ReSPECT study, that

CorMedix announces or publishes from time to time may change as more patient data become available or may be interpreted differently if

additional data is disclosed; estimates of total addressable market size; expectations regarding product utilization and sales; failure

to successfully conduct future clinical trials, including due to CorMedix’s or its partners’ potential inability to enroll

or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things;

development of unexpected safety or efficacy concerns related to CorMedix’s product candidates; expectations and timing regarding

clinical trials and development and expectations of CorMedix’s product pipeline; expectations regarding implementation and perceived

benefits of CorMedix’s products; continued pricing pressures and the impact of actions of governmental and private payers affecting

pricing of, reimbursement for, and patient access to pharmaceuticals; and reporting obligations related thereto, the expiration of intellectual

property protection for certain of the company's products and competition from generic and biosimilar products. Readers are cautioned

that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed

to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies

of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually

achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date

of this Current Report on Form 8-K. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and

does not intend to update these forward-looking statements, except as required by law.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated April 27, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: April 27, 2026

By:

/s/ Joseph Todisco

Name:

Joseph Todisco

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE DATED APRIL 27, 2026

EX-99.1

Filename: ea028764001ex99-1.htm · Sequence: 2

Exhibit 99.1

CORMEDIX Therapeutics AnnounceS POSITIVE Topline Results from PHASE III respect TriaL assessing Rezzayo® for the PROPHYLAXIS of

invasive fungal diseases in ALLOGENEIC Haematopoietic Stem Cell Transplantation PATIENTS

– The

study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –

– Study

showed favorable benefit for toxicity related discontinuations and drug-drug interactions –

– Rezafungin was well tolerated,

with a safety profile comparable to standard antimicrobial regimens –

Parsippany, NJ – April 27, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today announced positive Phase

III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin for injection) for prophylaxis of invasive

fungal diseases (IFDs) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

The ReSPECT Phase III

study, one of the largest anti-fungal multicenter, randomized, double-blind studies evaluated the efficacy and safety of once weekly rezafungin

(rezafungin acetate) compared with a standard antimicrobial regimen (SAR) for the prophylaxis of invasive fungal diseases, including infections

caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic

blood and marrow transplantation face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis, representing

a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected.

The ReSPECT study met

its primary endpoint for FDA and EMA for fungal-free survival at Day 90 showing non-inferiority vs. SAR, with 60.7% fungal-free survival

at Day 90 for rezafungin compared to 59.0% for standard antimicrobial regimen. This demonstrates that rezafungin’s

differentiated pharmacokinetics/pharmacodynamics (PK/PD) profile was comparable to the standard antimicrobial regimen (SAR) in reducing

the incidence of invasive fungal infections in a high-risk patient population. Rezafungin was well tolerated, with a safety profile

showing a favorable benefit/risk profile for immunocompromised patients.

The Phase III study topline

results demonstrated comparable efficacy against invasive infections from candida, aspergillus and pneumocystis in

both therapeutic arms, as well as comparable mortality. In addition, results showed a favorable profile in multiple secondary endpoints,

most notably treatment emergent adverse events leading to dose reduction, interruption or withdrawal of study drug, and treatment emergent

adverse events leading to study discontinuation.

“We believe this positive outcome of

the Phase III ReSPECT study meaningfully strengthens REZZAYO’s long-term potential value proposition to patients and

clinicians,” said Joseph Todisco, Chairman & Chief Executive Officer of CorMedix Therapeutics. “Preliminary topline

results for ReSPECT demonstrate clinical efficacy in prevention against all three measured pathogens, as well as positive

differentiation in certain safety related secondary endpoints, specifically drug-drug interactions and toxicity related

discontinuations, which positions REZZAYO well to become an attractive alternative to the standard anti-fungal regimen, if approved

by FDA for an expanded indication of prophylaxis of IFD. Our deepest gratitude goes out to the patients, their caregivers,

investigators and the study staff whose dedication and participation enabled this compelling clinical outcome.”

This clinical trial has been sponsored by

Mundipharma. Mundipharma has commercial rights to rezafungin outside the U.S. Mundipharma has partnered with Melinta

Therapeutics, LLC, a wholly owned subsidiary of CorMedix for US distribution of rezafungin. The companies anticipate a pre-NDA

submission meeting with FDA in the coming months, followed by a target submission of a supplemental New Drug Application (sNDA) to

the FDA in 2H26 based on the ReSPECT results.

About rezafungin

Rezafungin is a next generation echinocandin approved

for the treatment of candidemia and invasive candidiasis in adults.1,2 Invasive candidiasis continues to be an area of significant

unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available

treatments, the mortality rate for patients with invasive candidiasis is as high as 40%.3,4

Rezafungin has been studied for the prophylaxis

of invasive fungal diseases in adults undergoing allogeneic HSCT.

CorMedix estimates that the potential US market

opportunity for REZZAYO in prophylaxis exceeds $2 billion, based on internal analyses and assumptions. These estimates are forward-looking

statements and are subject to regulatory approvals, clinical practice considerations, and market adoption. Rezafungin has orphan drug

exclusivity through 2035 and patent coverage through 2038 in the U.S.

REZZAYO® is a Registered Trademark

of Mundipharma, used under license by Melinta Therapeutics LLC, a wholly owned subsidiary of CorMedix in the US.

About CorMedix

CorMedix

Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment

of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional

settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers.

Rezafungin is currently approved for the treatment of candidemia and invasive candidiasis in adults. For

more information visit: www.cormedix.com.

Forward-Looking Statements

This press release contains “forward-looking

statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933,

as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Forward-looking

statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,”

“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”

“project,” “seek,” “should,” “target,” “will,” “would,” and similar

expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts,

regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements

including, but not limited to statements regarding the risk that topline data from CorMedix’s and its partners’ clinical trials,

including the ReSPECT study, that CorMedix announces or publishes from time to time may change as more patient data become available or

may be interpreted differently if additional data is disclosed; estimates of total addressable market size; expectations regarding product

utilization and sales; failure to successfully conduct future clinical trials, including due to CorMedix’s or its partners’

potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory

approval, among other things; development of unexpected safety or efficacy concerns related to CorMedix’s product candidates; expectations

and timing regarding clinical trials and development and expectations of CorMedix’s product pipeline; expectations regarding implementation

and perceived benefits of CorMedix’s products; continued pricing pressures and the impact of actions of governmental and private

payers affecting pricing of, reimbursement for, and patient access to pharmaceuticals; and reporting obligations related thereto, the

expiration of intellectual property protection for certain of the company’s products and competition from generic and biosimilar products.

Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and

readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report

on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix

may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only

as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and

does not intend to update these forward-looking statements, except as required by law.

CorMedix Investor Contact:

Dan Ferry

Managing Director

LifeSci Advisors

daniel@lifesciadvisors.com

(617) 430-7576

References:

1. REZZAYO® United States Prescribing Information. Available at: chrome-https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217417s008lbl.pdf

(last accessed April 2026).

2. Bassetti M, et al. Crit Care 2019;23(1):219.

3. Cortegiani A, et al. Cochrane Database Syst Rev 2016;2016:Cd004920.

4. N. Zhang et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer Journal 2023

available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10188596/pdf/41408_2023_Article_853.pdf (last accessed April 2026).

GRAPHIC

Filename: ea0287640_ex99-1img1.jpg · Sequence: 6

Binary file (21796 bytes)

Download ea0287640_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 27, 2026

Entity File Number

001-34673

Entity Registrant Name

CORMEDIX INC.

Entity Central Index Key

0001410098

Entity Tax Identification Number

20-5894890

Entity Incorporation, State or Country Code

Entity Address, Address Line One

389 Interpace Parkway

Entity Address, Address Line Two

Suite 450

Entity Address, City or Town

Parsippany

Entity Address, State or Province

Entity Address, Postal Zip Code

07054

City Area Code

908

Local Phone Number

517-9500

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, $0.001 par value

Trading Symbol

CRMD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration